Literature DB >> 25734549

Combined Assessment of High-Sensitivity Troponin T and Noninvasive Coronary Plaque Composition for the Prediction of Cardiac Outcomes.

Gitsios Gitsioudis1, Alena Schüssler1, Eszter Nagy1, Pál Maurovich-Horvat1, Sebastian J Buss1, Andreas Voss1, Waldemar Hosch1, Nina Hofmann1, Hans-Ulrich Kauczor1, Evangelos Giannitsis1, Hugo A Katus1, Grigorios Korosoglou1.   

Abstract

PURPOSE: To determine the risk-stratification ability of plaque volume and composition assessment with cardiac computed tomographic (CT) angiography and high-sensitivity troponin T (hsTnT) in patients at intermediate risk for coronary artery disease (CAD).
MATERIALS AND METHODS: The study complied with the Declaration of Helsinki and was approved by the local ethics committee. All patients gave written informed consent. Five hundred twenty-one consecutive patients (mean age ± standard deviation, 62 years ± 10; 256 men and 265 women) were included in this prospective, observational, longitudinal, single-center study. Quantitative cardiac CT angiography analysis was performed in all patients (for 7690 coronary segments), whereas biomarkers (hsTnT and high-sensitivity C-reactive protein) were available in 408 patients (78%). To evaluate the incremental value of cardiac CT angiography and hsTnT for the prediction of cardiovascular events, multivariate Cox regression and integrated discrimination improvement analysis were applied.
RESULTS: In 521 patients, 13 hard cardiac events occurred during a mean follow-up period of 2.3 years ± 1.1 (median, 2.4 years; range, 0.5-4.5 years), while 23 patients underwent late coronary revascularization. The Duke clinical score was 51% ± 30, indicating intermediate risk. The presence of no plaques or purely calcified versus noncalcified plaques, plaque volume according to tertiles, and increased hsTnT (≥14 pg/mL) was independently associated with hard cardiac events (hazard ratio [HR] = 26.08, 95% confidence interval [CI]: 2.78, 244.99; HR = 12.14, 95% CI: 1.87, 78.74; and HR = 10.31, 95% CI: 2.72, 39.0, respectively; P < .01 for all). Patients with increased hsTnT and plaque burden (n = 53) showed the highest incidence for hard cardiac events (annual rate, 12.7%), followed by those with either increased hsTnT or plaque burden (n = 145; annual rate = 0.44%, P < .03), while those with lower hsTnT and plaque burden exhibited excellent outcomes and no hard event during the follow-up duration (n = 210; annual rate = 0%, P < .001).
CONCLUSION: Use of hsTnT as a marker of myocardial microinjury and cardiac CT angiography as a marker of the total atherosclerotic burden improves the prediction of cardiac outcome in patients with presumably stable CAD and may aid in personalized risk stratification in patients at intermediate risk.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25734549     DOI: 10.1148/radiol.15141110

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  8 in total

1.  Differences in the association of total versus local coronary artery calcium with acute coronary syndrome and culprit lesions in patients with acute chest pain: The coronary calcium paradox.

Authors:  Stefan B Puchner; Thomas Mayrhofer; Jakob Park; Michael T Lu; Ting Liu; Pal Maurovich-Horvat; Khristine Ghemigian; Daniel O Bittner; Jerome L Fleg; James E Udelson; Quynh A Truong; Udo Hoffmann; Maros Ferencik
Journal:  Atherosclerosis       Date:  2018-04-17       Impact factor: 5.162

2.  Combined non-invasive assessment of endothelial shear stress and molecular imaging of inflammation for the prediction of inflamed plaque in hyperlipidaemic rabbit aortas.

Authors:  Gitsios Gitsioudis; Yiannis S Chatzizisis; Peter Wolf; Anna Missiou; Antonios P Antoniadis; Dimitrios Mitsouras; Sönke Bartling; Zeynep Arica; Matthias Stuber; Frank J Rybicki; Max Nunninger; Christian Erbel; Peter Libby; George D Giannoglou; Hugo A Katus; Grigorios Korosoglou
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2016-03-24       Impact factor: 6.875

Review 3.  Bridging the gap for lipid lowering therapy: plaque regression, coronary computed tomographic angiography, and imaging-guided personalized medicine.

Authors:  Alan C Kwan; Konstantinos N Aronis; Veit Sandfort; Roger S Blumenthal; David A Bluemke
Journal:  Expert Rev Cardiovasc Ther       Date:  2017-07-06

4.  Commentary: Plaque Features and Epicardial Fat Volume for Cardiovascular Risk Assessment-A Key Role With Cardiac Computed Tomography?

Authors:  Christian Tesche; Alexander Giesen; Grigorios Korosoglou
Journal:  Front Cardiovasc Med       Date:  2022-04-29

5.  Circulating levels of cardiac troponin T are associated with coronary noncalcified plaque burden in HIV-infected adults: a pilot study.

Authors:  Parker Foster; Lori Sokoll; Ji Li; Gary Gerstenblith; Elliot K Fishman; Thomas Kickler; Shaoguang Chen; Hong Tai; Hong Lai; Shenghan Lai
Journal:  Int J STD AIDS       Date:  2018-10-31       Impact factor: 1.359

Review 6.  Computed Tomography and Cardiac Magnetic Resonance in Ischemic Heart Disease.

Authors:  Marc R Dweck; Michelle C Williams; Alastair J Moss; David E Newby; Zahi A Fayad
Journal:  J Am Coll Cardiol       Date:  2016-11-15       Impact factor: 24.094

7.  Determinants of Non-calcified Low-Attenuation Coronary Plaque Burden in Patients Without Known Coronary Artery Disease: A Coronary CT Angiography Study.

Authors:  Hiroki Yamaura; Kenichiro Otsuka; Hirotoshi Ishikawa; Kuniyuki Shirasawa; Daiju Fukuda; Noriaki Kasayuki
Journal:  Front Cardiovasc Med       Date:  2022-04-07

8.  Epicardial Adipose Tissue Is Associated with Plaque Burden and Composition and Provides Incremental Value for the Prediction of Cardiac Outcome. A Clinical Cardiac Computed Tomography Angiography Study.

Authors:  Gitsios Gitsioudis; Christina Schmahl; Anna Missiou; Andreas Voss; Alena Schüssler; Hassan Abdel-Aty; Sebastian J Buss; Dirk Mueller; Mani Vembar; Mark Bryant; Hans-Ulrich Kauczor; Evangelos Giannitsis; Hugo A Katus; Grigorios Korosoglou
Journal:  PLoS One       Date:  2016-05-17       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.